{"entity":{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","aka":[],"tldr":"Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial.","summary":"Developed by Shanghai Allist Pharmaceuticals; approved by the NMPA in March 2021 for EGFR T790M-positive NSCLC after earlier EGFR inhibitors and in June 2022 for first-line EGFR-mutant NSCLC on FURLONG (358 patients: median progression-free survival 20.8 versus 11.1 months with gefitinib, hazard ratio 0.44). A higher dose is being developed for EGFR exon 20 insertions, where ArriVent BioPharma holds ex-China rights and is running the global FURVENT phase 3 trial. Adjuvant and central nervous system studies continue.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Furmonertinib","links":[{"label":"Shanghai Allist Pharmaceuticals","url":"https://www.allist.com.cn/"},{"label":"FURLONG (Lancet Respir Med 2022)","url":"https://doi.org/10.1016/S2213-2600(22)00168-0"},{"label":"NMPA (National Medical Products Administration)","url":"https://www.nmpa.gov.cn"}],"tags":["china"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["egfr"],"drugs":[],"companies":["allist"],"institutions":[],"pathways":["ras-mapk"],"terms":["egfr-mutation-subtypes"],"trials":["furlong","nct05607550","nct07185997","nct06962865","nct07622186","nct05994131","nct04853342","nct05466149","nct06970639"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Ivesa","code":"AST2818, alflutinib","modality":"Small-molecule third-generation EGFR TKI","mechanism":"Irreversible third-generation EGFR inhibitor active against sensitising mutations and T790M with a trifluoroethoxy pyridine that improves brain penetration; its main metabolite is also active.","approvals":[{"region":"China","year":2021,"indication":"EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy"},{"region":"China","year":2022,"indication":"First-line EGFR exon 19 deletion or L858R NSCLC (FURLONG)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/furmonertinib/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"arrivent","kind":"company","name":"ArriVent BioPharma","route":"/companies/arrivent/"},{"id":"minghui-pharmaceutical","kind":"company","name":"Minghui Pharmaceutical","route":"/companies/minghui-pharmaceutical/"},{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}],"pathway":[{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"}],"term":[{"id":"egfr-mutation-subtypes","kind":"term","name":"EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)","route":"/terms/egfr-mutation-subtypes/"}],"trial":[{"id":"nct06962865","kind":"trial","name":"A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv","route":"/trials/nct06962865/"},{"id":"nct06970639","kind":"trial","name":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","route":"/trials/nct06970639/"},{"id":"nct07229599","kind":"trial","name":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer","route":"/trials/nct07229599/"},{"id":"nct07622186","kind":"trial","name":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07622186/"},{"id":"nct05466149","kind":"trial","name":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion","route":"/trials/nct05466149/"},{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/"},{"id":"nct06674343","kind":"trial","name":"Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations","route":"/trials/nct06674343/"},{"id":"nct05334277","kind":"trial","name":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","route":"/trials/nct05334277/"},{"id":"nct05994131","kind":"trial","name":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","route":"/trials/nct05994131/"},{"id":"nct05607550","kind":"trial","name":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With","route":"/trials/nct05607550/"},{"id":"nct07185997","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W","route":"/trials/nct07185997/"},{"id":"nct04853342","kind":"trial","name":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","route":"/trials/nct04853342/"}]}}